Diabetic Foot Ulcers - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 131
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D232529D726EN
Leaflet:

Download PDF Leaflet

Diabetic Foot Ulcers - Pipeline Review, H2 2017
Diabetic Foot Ulcers - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2017, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 7, 1, 20, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Diabetic Foot Ulcers - Overview
Diabetic Foot Ulcers - Therapeutics Development
Diabetic Foot Ulcers - Therapeutics Assessment
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
Diabetic Foot Ulcers - Drug Profiles
Diabetic Foot Ulcers - Dormant Projects
Diabetic Foot Ulcers - Discontinued Products
Diabetic Foot Ulcers - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Diabetic Foot Ulcers, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, H2 2017
Diabetic Foot Ulcers - Pipeline by Boston Therapeutics Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by Celgene Corp, H2 2017
Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2017
Diabetic Foot Ulcers - Pipeline by Energenesis Biomedical Co Ltd, H2 2017
Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by Genentech Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H2 2017
Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2017
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H2 2017
Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H2 2017
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H2 2017
Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H2 2017
Diabetic Foot Ulcers - Pipeline by ProMetic Life Sciences Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by Serodus ASA, H2 2017
Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H2 2017
Diabetic Foot Ulcers - Pipeline by Stratatech Corp, H2 2017
Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2017
Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H2 2017
Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H2 2017
Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H2 2017
Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H2 2017
Diabetic Foot Ulcers - Dormant Projects, H2 2017
Diabetic Foot Ulcers - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diabetic Foot Ulcers - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diabetic Foot Ulcers - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diabetic Foot Ulcers, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

ANP Technologies Inc
Anterogen Co Ltd
Boston Therapeutics Inc
CardioVascular BioTherapeutics Inc
Celgene Corp
Chrysalis BioTherapeutics Inc
CytoTools AG
Energenesis Biomedical Co Ltd
EyeGene Inc
FirstString Research Inc
Genentech Inc
GlaxoSmithKline Plc
Human Stem Cells Institute
Izun Pharmaceuticals Corp
Lakewood-Amedex Inc
MediWound Ltd
Oneness Biotech Co Ltd
Osiris Therapeutics Inc
Pherecydes Pharma SA
ProMetic Life Sciences Inc
Serodus ASA
Stempeutics Research Pvt Ltd
Stratatech Corp
TechnoPhage SA
Topadur Pharma AG
USV Pvt Ltd
viDA Therapeutics Inc
ViroMed Co Ltd
Skip to top


Gastric Ulcers - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 45 pages
Gastric Ulcers - Pipeline Review, H1 2018 US$ 2,000.00 Mar, 2018 · 44 pages

Ask Your Question

Diabetic Foot Ulcers - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: